HC Wainwright Begins Coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL)

Analysts at HC Wainwright began coverage on shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) in a report released on Wednesday, Zacks reports. The brokerage set a “strong-buy” rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Madrigal Pharmaceuticals’ Q1 2027 earnings at ($0.29) EPS, Q2 2027 earnings at $1.60 EPS, Q3 2027 earnings at $3.13 EPS and Q4 2027 earnings at $4.16 EPS.

Other equities analysts also recently issued research reports about the company. Wolfe Research raised Madrigal Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $605.00 target price on the stock in a research report on Tuesday, August 4th. The Goldman Sachs Group initiated coverage on Madrigal Pharmaceuticals in a research note on Thursday, September 24th. They issued a “buy” rating and a $704.00 price target for the company. Truist Financial restated a “buy” rating and issued a $743.00 price target (up from $709.00) on shares of Madrigal Pharmaceuticals in a research note on Wednesday. Wells Fargo & Company assumed coverage on Madrigal Pharmaceuticals in a report on Monday, July 27th. They issued an “overweight” rating and a $685.00 price objective on the stock. Finally, Barclays lowered their price objective on Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating on the stock in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $706.87.

Madrigal Pharmaceuticals Stock Up 1.0%

Shares of MDGL opened at $400.43 on Wednesday. Madrigal Pharmaceuticals has a 52 week low of $353.54 and a 52 week high of $615.00. The firm has a market cap of $9.25 billion, a P/E ratio of -66.96 and a beta of -0.98. The firm’s 50-day simple moving average is $492.40 and its 200 day simple moving average is $498.45. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.94 and a current ratio of 3.20.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 earnings per share for the quarter, beating the consensus estimate of ($1.09) by $2.92. The firm had revenue of $431.27 million for the quarter, compared to analysts’ expectations of $404.17 million. Madrigal Pharmaceuticals had a negative net margin of 10.89% and a negative return on equity of 27.93%. During the same period in the prior year, the firm earned ($5.08) EPS. On average, analysts forecast that Madrigal Pharmaceuticals will post -7.03 earnings per share for the current year.

Insider Transactions at Madrigal Pharmaceuticals

In other news, CEO William Sibold sold 5,221 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $542.39, for a total value of $2,831,818.19. Following the completion of the sale, the chief executive officer directly owned 197,746 shares in the company, valued at approximately $107,255,452.94. The trade was a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Shannon T. Kelley sold 664 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $514.97, for a total transaction of $341,940.08. Following the completion of the sale, the general counsel owned 11,474 shares of the company’s stock, valued at approximately $5,908,765.78. The trade was a 5.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 12,247 shares of company stock valued at $6,581,182 in the last three months. Insiders own 17.60% of the company’s stock.

Institutional Investors Weigh In On Madrigal Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in MDGL. Jupiter Topco LLC acquired a new stake in shares of Madrigal Pharmaceuticals during the second quarter valued at about $1,039,650,000. Paulson & CO. Inc. bought a new stake in shares of Madrigal Pharmaceuticals during the second quarter worth about $719,524,000. BlackRock Inc. bought a new stake in shares of Madrigal Pharmaceuticals during the second quarter worth about $644,753,000. Janus Henderson Group PLC boosted its position in Madrigal Pharmaceuticals by 27.4% during the 1st quarter. Janus Henderson Group PLC now owns 2,018,647 shares of the biopharmaceutical company’s stock worth $1,051,727,000 after buying an additional 433,804 shares during the period. Finally, William Blair Investment Management LLC bought a new stake in Madrigal Pharmaceuticals during the 2nd quarter worth approximately $174,038,000. Institutional investors and hedge funds own 98.50% of the company’s stock.

Trending Headlines about Madrigal Pharmaceuticals

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Q3 results substantially beat expectations. Madrigal reported earnings of $1.83 per share, versus the consensus estimate of a $1.09 loss, and revenue of $431.3 million, ahead of the $404.2 million estimate. Rezdiffra sales growth helped drive the results, with coverage reporting sales surpassed $1 billion. Madrigal Q3 results
• Positive Sentiment: Analysts raised price targets and maintained Buy ratings. Canaccord lifted its target to $633 from $612, Truist to $743 from $709, and Citi to $760 from $725. The upgrades reflect substantial potential upside, though targets are analysts’ estimates, not guarantees. Canaccord rating Truist rating Citi rating
• Neutral Sentiment: Clinical development continues, but key data are not imminent. Madrigal expects the MAESTRO-NASH OUTCOMES readout in late 2027 and is planning a 2,000-plus-patient MAESTRO-CSPH study. These programs offer longer-term potential, but their timelines mean they are less likely to provide a near-term catalyst. Madrigal clinical plans
• Negative Sentiment: Legal investigations and profit-sustainability questions remain risks. Two law firms announced investigations into potential securities-law violations; these are allegations under investigation, not findings of wrongdoing. Separate coverage cited investor concerns about near-term profitability, which could temper the reaction to the strong quarterly beat. Kirby McInerney investigation notice Kaplan Fox investigation notice

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal’s lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis.